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Objective: To evaluate the impact of a Pharmaceutical Care service in the identiﬁ  cation and 
resolution of drug-related problems (DRPs) and in quality of life (QoL) of a group of elderly 
outpatients with chronic health conditions.
Methods: 30 outpatients (aged 60–75-years old) were followed between August 2003 and 
July 2004 at a primary health care unit in Ribeirão Preto (SP), Brazil. Patients were scheduled 
monthly to meet with the researcher, who provided Pharmaceutical Care service (the interven-
tion). Through Pharmaceutical Care, the pharmacist worked with the patient and other care 
providers to improve outcomes of drug therapy through focused education, care planning, and 
monitoring. Intervention outcomes were the number of DRPs prevented or resolved, and the 
impact on QoL. The Short Form-36 health survey was used to measure changes in QoL.
Results: The mean age of patients was 66 ± 5 years, 21 of whom had low literacy. During 
the study, 92 DRP were identiﬁ  ed, 3.0 ± 1.5 problems per patient. By the end of the study, the 
interventions solved 69% of actual DRP and prevented 78.5% potential DRP. In addition, QoL 
showed improvement in 22 patients after DRP resolution or prevention.
Conclusion: Despite the limitations in this study that may affect generalizability of the results, 
this study demonstrates that humanistic and behavioral interventions based on the Pharmaceuti-
cal Care model were capable in reducing DRPs, and improve QoL in patients.
Keywords: elderly, pharmaceutical care, quality of life
Introduction
In Brazil, the increase in the absolute number of elderly persons with chronic health 
conditions has been reported to be one of the determining factors in the rise in medi-
cation use (Rozenfeld 2003). Although there have been no studies about drug-related 
morbimortality in Brazilian population, drugs have been identiﬁ  ed as the ﬁ  rst cause of 
intoxication in this country since 1996 (SINITOX 2002). These data indicated the need 
to adopt new models of care that prevent drug-related morbimortality, and improve 
the population’s Quality of Life (QoL).
Globally, there have been signiﬁ  cant changes in health care systems in respect 
of their quality and processes, and this had been speciﬁ  cally demonstrated in the 
practice of pharmacy. A dramatic shift in the way pharmacy had been practiced was 
demonstrated in the newly emerging Pharmaceutical Care practice, deﬁ  ned as ‘the 
responsible provision of drug therapy to achieve deﬁ  nite outcomes that improve a 
patient’s quality of life’ (Hepler and Strand 1990). This deﬁ  nition, which placed 
QoL in the core of the Pharmaceutical Care philosophy, was subsequently adopted 
worldwide (Kheir et al 2004).Therapeutics and Clinical Risk Management 2007:3(6) 990
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Quality of life is generally considered a multidimensional 
construct that includes physical, mental, and social function-
ing, as well as perceptions of general well-being (Hays et al 
2000). Nowadays, QoL can be measured objectively with 
questionnaires (instruments) possessing sufﬁ  cient sensitiv-
ity to change, reliability and validity properties (Siedl and 
Zannon 2004). It has been a fundamental research topic in 
health, as its results are important to assess the effectiveness 
of care as well as to obtain social and health funding (Okano 
et al 2001).
Therefore, the purpose of this study was to evaluate the 
effect of pharmaceutical interventions in the reduction of 
drug-related problems (DRP) and improvement of QoL in a 
group of elderly outpatients with chronic health conditions.
Methods
A prospective study was conducted at a primary health care 
unit (PHCU) in Ribeirão Preto (SP), Brazil, from August 
2003 to July 2004. The site was chosen because 300 of the 
1500 patients have hypertension, and the center’s health care 
providers identiﬁ  ed 40% (120) of non-adherence as a primary 
reason for poor treatment outcomes. At the PHCU, the out-
patients were attended by four physicians, two dispensing 
pharmacists and a researcher pharmacist.
Patients
During a week period, all hypertensive patients who came 
to the ambulatorial care pharmacy of PHCU to receive their 
medication were identiﬁ  ed as potential candidates for the 
study. Patients were eligible to participate if they met three or 
more of the following criteria (Koecheler et al 1989): ﬁ  ve or 
more drugs in their drug therapy regimen, twelve or more 
doses per day, a medication regimen that had changed four 
or more times in the past year, three or more co-morbidities, 
a history of medication non-compliance, and presence 
of at least one drug that requires therapeutic monitoring 
(Appendix A). Exclusion criteria were stage 3 hypertension 
(systolic  180 mmHg and/or diastolic pressure  110 mmHg 
based on JNC-VI criteria), an identiﬁ  ed secondary cause of 
hypertension, such as chronic renal disease, renovascular 
disease, pheochromocytoma, Cushing’s syndrome, and pri-
mary aldosteronism; or if the patient missed more than three 
appointments during the study.
Out of 300 hypertensive patients, 90 eligible patients 
were invited. Of these, 16 refused to participate, 74 accepted 
to be included, but 15 were eventually excluded because 
of their age. From the remaining 59, thirty patients com-
pleted the entire study, attending all of the interviews with 
the researcher and provided complete data. The remaining 
29 patients declined to participate or rejected by the research 
team; and the most common reasons for declining/rejection 
were lack of time (n = 11), missing more than one scheduled 
interview (n = 10), patient’s lack of belief in any health-
related added value in the study (n = 6), and patient moved 
out of the area (n = 2). The nature of the study was explained 
to the patients, and an informed consent forms were signed 
by those eligible and interested in participating.
Pharmaceutical Care program
Patients were scheduled to see the pharmacist at least once 
every month at the PHCU for a year. Following a structured 
pharmaceutical care methodology, the pharmacist conducted 
interviews lasting from 30 to 40 minutes, and addressed a 
number of issues (from socio-demographic variables col-
lected at the initial interview, to medical and drug history, 
identiﬁ  cation of problems and needs, assessment, and care 
planning) (Currie et al 2003). The aim for the provision of 
Pharmaceutical Care was to provide individualized care tai-
lored to the health needs of the patient in order to improve 
therapy outcomes, with special emphasis on quality of life 
(QoL). The two major areas addressed through the process 
were health education and drug therapy (Lyra et al 2005). 
The process aimed at achieving personal transformation 
through focusing into three key consciousness-raising 
experiences: relating and reﬂ  ecting on experience; explora-
tion and problem solving; and taking thoughtful action. These 
steps provide a framework for Freire’s participatory social 
orientation approach to the design of effective educational 
strategies in health. While originally applied to the teaching 
of basic literacy skills to adults in Brazil, it has been used 
internationally in health education (Roter 2001; Freire 1983; 
Roter 2000).
The educational part of the intervention consisted of: 
orientation concerning chronic health conditions (nature, 
causes and treatment) and changes in lifestyle, the recognition 
of signs and symptoms caused by medication (effectiveness 
and safety) and the encouragement of patients to participate 
actively in designing his/her drug therapy regimen.
The pharmacist evaluated patients individually to iden-
tify actual and potential DRPs, which were categorized in 
terms of need, effectiveness and safety (Comité de Consenso 
2002 – Appendix). All the information was recorded in 
dedicated database that was updated monthly. Drug therapy 
interventions also consisted of: assessment of drug history 
(current and past medication history, need for drug therapy, 
compliance with drug therapy), identiﬁ  cation, prevention, Therapeutics and Clinical Risk Management 2007:3(6) 991
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and resolution of DRPs (actual and potentials), use and stor-
age of medicines (prescription, over-the-counter (OTC), and 
herbal drugs), and the level and ability for the implementation 
of adherence-improving strategies.
Evaluation of QoL
In this study, the Medical Outcomes Study Short Form 36 
(SF-36®) – a well established generic health status question-
naire- was chosen because of its applicability to a variety of 
disease sates, ease of administration, international application 
and documented validity (Ware and Sherbourne 1992).
The SF-36 version that was used in the current study 
had been adapted and validated for Brazilian-Portuguese 
(Ciconelli et al 1999). The SF-36 contains 36 multiple choice 
questions distributed in eight domains, each of which evalu-
ates one of the following characteristics: functional ability 
(10 items), physical appearance (4 items), pain (2 items), 
global health state (5 items), vitality (4 items), social situa-
tion (2 items), emotional status (3 items) and mental health 
(5 items). Each domain was transformed to a scale ranging 
from 0 to 100, in which the highest score represented the 
best QoL level. For each unanswered domain, the average 
value of the other items in the same domain was consid-
ered. The SF-36 was administrated to patients at baseline 
(ﬁ  rst interview) and at the end of the study (12-months). 
The pharmacist researcher was trained to apply the SF-36 
instrument.
Statistical analysis
The paired t test was used to measure differences in DRP and 
QoL between baseline (August 2003) and the end (July 2004) 
of this study. A difference of 5 points in changed SF-36 
domain scores was considered clinically meaningful (Ware 
et al 1995). All analyses used SPSS (version 12, SPSS Inc., 
Chicago, IL). A signiﬁ  cance level of 0.05 was adopted for 
all statistical tests. All results were validated by means of 
Wilcoxon’s Rank-sum test.
Results
Socio-demographic and health situation 
proﬁ  le
The mean age of patients was 66 ± 5-years, 20 of whom were 
women (n = 30). 21 (71%) of the interviewees reported low 
literacy. In Brazil, literate is a person who can both read 
and write at least a simple statement in a language he or she 
knows (language – Portuguese) (UNESCO 2006). There was 
a predominance of retirees/pensioners and housewives (63% 
and 27% respectively). The mean number of chronic health 
conditions per elderly individual corresponded to 3.5 ± 1.5. In 
this study, 17 (56.5%) of the patients reported hypertension, 
diabetes mellitus and hyperlipidemia diagnosed more than 
10-years before. Due to various morbidities, each patient had 
an average of ﬁ  ve physicians’ appointments with different 
specialists per year.
Drug therapy proﬁ  le
During the study period, 250 different medicines were used 
(mean 8.5 ± 4 drugs per patient), and the majority (81%) were 
prescribed by a physician. Twenty patients were taking more 
than ﬁ  ve different drugs at the same time.
Evaluation of Pharmaceutical Care 
interventions
In this study, 590 interventions were performed and docu-
mented. Of these, 214 were concerned drug therapy and 376 
involved provision of education (Tables 1 and 2). These 
interventions were equally distributed among the different 
chronic health conditions that the patients suffered.
Ninety two DRPs were identiﬁ  ed during the study, aver-
aging 3.0 ± 1.5 problems per patient. There was higher inci-
dence of problems in the of the Safety category (64%), mainly 
in drug classes such as: diuretics (12 [19%]), analgesics (10 
[16%]), calcium channel blockers (9 [14%]) and angiotensin-
converting-enzyme (ACE) inhibitors (8 [13%]).
Twenty one patients showed a mean of 2.6 actual DRP 
and 0.5 potential DRP. 65% of 214 drug therapy interven-
tions required a physician’s approval or agreement. The 
physicians agreed to change 86% of drug therapy regimen. 
By the end of the study, the interventions resolved 69% of 
actual DRPs and prevented 78% potential DRPs. The results 
demonstrated an average of 4 ± 2 Pharmaceutical Care inter-
views to identify and solve DRPs. All of the health education 
interventions that were made were accepted by the patients 
and implemented by them.
Some actual and potential DRP remained unresolved or 
were not prevented. The resolution and prevention of these 
DRP required modiﬁ  cations in drug regimens that relied 
exclusively on a medical decision.
Details involving socio-demographic proﬁ  le and the 
evaluation of Pharmaceutical Care interventions are well 
described in a previous publication (IV DBHA 2002).
Analysis of QoL
At baseline of this study, there was a trend for poor QoL in 
patients who had more diseases and used more medications 
(Figure 1 and 2, respectively).Therapeutics and Clinical Risk Management 2007:3(6) 992
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At the end of the study, the statistically significant 
difference were found in SF-36 domains (p   0.05) of 
physical aspects, pain, general health status, vitality, social 
and emotional aspects after interventions (Table 3). Score 
in mental health domain also was higher but did not achieve 
statistical signiﬁ  cance (p = 0.05).
The results of changes in QoL were evaluated and com-
pared with number of interventions made and DRPs resolved 
or prevented (Table 4). Twenty two patients presented with 
mean change in QoL score of  5 units after DRP resolution 
or prevention. There was a proportional converse relationship 
between QoL and the number of DRPs, after the interven-
tions. See Figure 3.
Discussion
This study provided evidence for the beneﬁ  ts of a patient-
focused role of the pharmacist in identifying and resolving 
drug-related problems in the patient population studied.
The large number of medications taken and the 
occurrence of problems associated to these drugs suggested 
that medications are potential harmful agents to the health 
of the elderly population and that they can cause an array of 
symptoms ranging from orthostatic hypotension and gastritis 
to dizziness and muscle cramps. These symptoms neces-
sitated the withdrawal of the drug in many cases. However, 
collaborative work between the pharmacist and physicians 
was successful in making tangible changes in the drug regi-
mens and introduced simple therapeutic regimens tailored 
to the needs and circumstances of the individual patient. 
The co-operation between the pharmacist and the clinician 
also was key to resolving and/or preventing DRPs in PHCU. 
Other studies showed positive results of interventions that 
lead to the resolution and prevention of DRPs, reduction of 
treatment costs and overall satisfaction with pharmaceutical 
care program (Mehos et al 2000; Bernsten et al 2001; Geber 
et al 2002; Vivian 2002).
Table 1 Quantitative distribution of the educational interventions, Ribeirão Preto, 2004
Educational interventions  Frequency
Counseling about a new drug prescribed  30
Counseling about doubts related to drug administration  40
(dose, schedule, duration of drug therapy, route of administration) 
Counseling about use of drug   14
Counseling about potential drug-drug interactions  36
Counseling about actual or potential adverse drug reactions   38
Counseling about drug home storage  45
Counseling about heath problem  41
Counseling about heath education  38
Counseling about lifestyle modiﬁ  cations  56
Referring to other health care providers  28
Other important educational counseling’s about drug therapy  10
TOTAL  376
Table 2 Quantitative distribution of the drug therapy interventions, Ribeirão Preto, 2004
Drug therapy interventions by the pharmacist (all accepted)  Frequency
Doctor advised to prescribed an additional drug therapy   8
Patient advised to stop taking unnecessary non-prescribed drug therapy   21
Doctor advised to withdraw unnecessary drug therapy   18
Doctor advised to change prescribed drug therapy  5
Doctor advised to increase frequency of a prescribed drug therapy  24
Doctor advised to increase dosage of a prescribed drug therapy  21
Helped patients re-schedule new drug regimen prescribed  32
Patient or doctor advised to switch/substitute the medication to generics  8
Pharmacist suspended drug therapy because of adverse drug reaction  50
Doctor advised to decrease frequency of a prescribed drug therapy  6
Doctor advised to r decrease dosage of a prescribed drug therapy  9
Adjusting schedule of taking medicines (preventative therapy)  12
TOTAL  214Therapeutics and Clinical Risk Management 2007:3(6) 993
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Most of the patients in this study had low literacy rates. In 
Brazil, individuals with reduced education levels are approxi-
mately 5 times as likely to have health problems (Rosa et al 
2003). In this situation, the educational interventions could 
contribute to awareness development and to the exchange 
of experiences. This would also be expected to introduce 
or improve a process of humanization, replacing the domi-
nant formal practices that kept the patients at a comfortable 
distance and separated them form reality. Empowering 
patients through more involvement in their care builds their 
conﬁ  dence and helps in a process of personal transformation 
and realization of a state of ‘critical consciousness’ (Roter 
et al 2001).
The predominance of retirees/pensioners and housewives 
was high is this sample. According to Rosa et al, retirees 
and housewives are almost 8 times as likely to present with 
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morbidities (Rosa et al 2003). In our study, patients presented 
with at least two concurrent chronic health conditions; as a 
consequence they had to be treated by different specialist 
physicians, which needed polypharmacy and subsequently 
created the need for comprehension about complex drug ther-
apy regimen. In the literature, it has been demonstrated that 
the number of drugs prescribed increases with the number 
of physicians seen (Rollason and Vogt 2003). In the USA, 
for example, 43% of the patients use medication prescribed 
by more than two physicians, which increases the risk of 
redundancy and drug interaction (Steinbrook 2002).
The high level of medication consumed and the occur-
rence of an associated high incidence of DRPs suggested that 
the medications were potential harmful agents to the health 
of the elderly population and that they can cause an array of 
symptoms ranging from orthostatic hypotension and gastritis 
to dizziness and muscle cramps. These symptoms neces-
sitated the withdrawal of the drug in many circumstances. 
However, collaborative work between the pharmacist and 
physicians succeeded in making tangible changes in drug 
regimens and introduced simple therapeutic regimens tailored 
to the needs and circumstances of the individual patient. The 
co-operation between the pharmacist and the clinician also 
was key to resolving and/or preventing DRPs in PHCU. 
Other studies showed positive results of interventions that 
Table 3 QoL scores before and after the intervention as 
assessed by the SF-36, Ribeirão Preto, 2004
Domain Before  (n  = 30) After  (n  = 30) p- 
  Md (Q1, Q3)  Md (Q1, Q3)  value
Functional capacity  87.5 (70; 95)  87.5 (66; 100)  0.796
Physical aspects  100 (25; 100)  100 (100; 100)  0.002*
Pain  61 (41; 75)  72 (61; 100)  0.006*
General health status  72 (55; 87)  79.5 (62; 91)  0.012*
Vitality  60 (39; 80)  75 (60; 90)  0.000*
Social aspects  81 (50; 100)  100 (87.5; 100)  0.001*
Emotional aspects  100 (67; 100)  100 (100; 100)  0.013*
Mental Health  68 (60; 93)  76 (66; 92)  0.182
n = 30, Md = mean, Q1 and Q3 = quartiles, * = statistically signiﬁ  cant difference, 
p   0.05.
Table 4 Drug-related problems and QoL before and after the intervention per individual patient
Patient Before  (n  = 30)    Number of   After (n = 30)   Improvement
  DRP   QoL  Interventions  DRP Solved or   QoL  DRP (%)  QoL
 identiﬁ  ed      Prevented     
1 6  55.6  28  6  85.1  100  29.5
2 2  73.0  31  2  92.9  100  19.9
3 3  85.5  29  3  91.0  100  5.5
4 1  59.5  15  0  90.0  0  30.5
5 4  54.3  6  3  62.9  75  8.6
6 2  63.3  30  2  72.1  100  8.8
7 5  91.6  9  1  95.9  80  4.3
8 4  34.1  30  4  50.0  100  15.9
9 4  53.4  9  3  81.3  75  27.8
10 2  41.8  32  2  92.1  100  50.3
11 6  70.1  10  1  75.1  83.3  5.0
12 1  51.9  8  0  64.9  0  13.0
13 2  77.8  13  2  85.0  100  7.3
14 7  33.9  16  5  47.1  71.4  13.2
15 3  44.3  13  2  73.8  66  29.5
16 5  75.9  13  4  81.4  80  5.5
17 1  84.5  32  1  91.8  100  7.3
18 3  43.1  29  3  83.3  100  40.2
19 5  85.6  12  2  95.4  40  9.8
20 2  91.8  11  1  99.5  50  7.8
21 1  83.9  28  1  88.9  100  5.0
22 2  94.1  31  2  96.9  100  2.8
23 2  66.9  28  2  80.9  100  14.0
24 3  45.8  12  2  74.3  60  28.5
25 2  85.8  27  2  91.6  100  5.9
26 2  83.9  24  1  89.5  50  5.6
27 3  81.1  13  2  82.8  66  1.6
28 1  86.0  11  0  80.3  0  –5.7
29 1  97.1  30  1  97.8  100  0.6
30 6  82.5  10  3  84.9  50  2.4Therapeutics and Clinical Risk Management 2007:3(6) 995
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lead to the resolution and prevention of DRPs, reduction of 
treatment costs and overall satisfaction with pharmaceutical 
care program (Mehos et al 2000; Bernsten et al 2001; Geber 
et al 2002; Vivian 2002).
Generic instruments, such as the SF-36, can accurately 
assess all signiﬁ  cant health aspects and reﬂ  ect the impact 
of a disease on an individual (Fayers 2000). These types of 
instruments have been used to study groups of patients with 
different diseases, ambulatory populations, and populations 
with chronic health conditions.
The ﬁ  ndings obtained in baseline of our study suggest an 
inverse relationship between the number of health conditions 
suffered by the patient and QoL. It also provides evidence 
of an inverse relationship between QoL and the number of 
medications taken at the same time by the patient. These 
are important ﬁ  ndings because often the goal of therapy is 
to improve QoL, as was indeed the cases in several other 
studies which reported QoL improvements as a result of the 
introduction of drug therapy, for example in patients with 
asthma (Kheir 2001), diabetes (Cranor and Christensen 
2003) and migraine (Alsuwaidan 1998). In our case, it seems 
polypharmacy might be the culprit, especially when there is 
involvement of prescription ands non-prescription drugs.
One of the important aspects of using QoL instruments 
in intervention studies is the measurement properties of the 
questionnaire used. In case of the Sf-36, patients are not 
shown their ﬁ  rst visit’s scores at the second data collection 
visit. This is not a requirement when completing the SF-36 
(while it is required in some other QoL instruments like the 
Asthma Quality of Life Questionnaire, where it is assumed 
that informing patients of their previous health status, subjec-
tively assessed, would improve the instrument’s sensitivity). 
However, showing the patients their previous scores would 
have violated the structured method by which the SF-36 is 
used. Issues regarding sensitivity to change of the SF-36 are 
discussed below.
In this study, there was a trend for QoL to decline in 
7 domains over time. However, functional capacity was 
the only domain that remained stable, probably due to the 
physical decline that is characteristic of aging, associated 
with multiple biopsychosocial aspects that were present in 
our population of patients. Other studies showed positive 
outcomes for functional capacity, although the differences 
had been insigniﬁ  cant after 6-months of follow-up (Carter 
et al 1997; Bernsten et al 2001; Okamoto and Nakahiro 
2001). In the elderly, QoL is understood in terms of health 
and functional capacity and often associated with the degree 
of personal dependence and autonomy (the ability for self 
rule). This dependence can result from biological transforma-
tions (into disability) as it can from social transformation. 
Consequently, this subject should not only be linked to 
health promotion, but also to the persons’ social and cultural 
contexts (Cuellar and Fitzsimmons 2003). Actually, this 
emphasizes the humanistic nature and relevance of QoL and 
suggests the need for a form of pharmaceutical practice that 
is humane as much as it is professional.
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Malone and colleagues afﬁ  rmed that the SF-36 may not 
be sensitive enough to detect more changes in QoL that are 
attributable to pharmacist interventions (Malone et al 2001). 
Most of studies carried out in community pharmacies and 
hospital outpatient clinics in the USA and Europe which only 
applied the SF-36 did not demonstrate statically signiﬁ  cant 
effects on elderly QoL (Billups et al 2000; Bernsten et al 
2001; Malone et al 2001; Volume et al 2001). Otherwise, 
studies without a control group demonstrated that pharma-
cist interventions obtained positive results on one or more 
domains of QoL when compared with research with a control 
group, although the difference had not been statistically 
signiﬁ  cant (Pickard and Hung 2006).
According to the literature, the nature of interventions 
could be an important aspect for the failure in obtaining 
positive outcomes for QoL (Kheir et al 2001; Melchiors 
2005). Traditional approaches to teaching, in which patients 
are treated as passive and dependent objects, reinforce 
powerlessness and helplessness (Roter et al 2001). More-
over, traditional and purely pharmacological interventions 
can be very invasive in order to produce effective changes 
in QoL domains and to be detected by not very sensitive 
instruments (Kheir et al 2004). Adults, mainly elderly with 
low literacy, need a different approach to engage with 
the interventions. In comparison, Pharmaceutical Care 
is basically a behavioral intervention that may achieve 
positive outcomes, with subtle changes in QoL domains 4. 
Actually, interventions aimed at inﬂ  uencing behavior and 
awareness requires construction of therapeutic relationship, 
self-directed orientation, patient-centeredness, valorization 
of life experience, recognition of social roles, long periods 
of follow-up with a view to obtaining signiﬁ  cant and mea-
surable changes (Roter 2000; Grueninger 1995). Therefore, 
the interventions based on awareness-raising in this study 
were probably responsible for the positive outcomes in 
terms of elderly QoL.
Limitations
The limitation of this study could be summarized as follows: 
the researcher’s experience in pharmaceutical care, sample 
size, ability of researcher to apply SF-36 and program con-
ducted in only one setting.
The researcher’s lack of experience in pharmaceutical 
care (a relatively new practice in the ﬁ  led of pharmacy) 
may have prevented the detection of more DRPs. These 
undetected DRPs may have negatively impacted on the 
patients’ QoL hence affecting the degree of improvement 
resulting from the intervention. Other studies demonstrated 
that the major difﬁ  culty to improve QoL in the elderly was 
because of the variations in pharmacists’ education (Billups 
et al 2000; Malone et al 2001; Garção et al Cabrita 2002). 
Therefore, a longer training period for the researcher might 
have produced better results.
Although the SF-36 has been frequently used in pharma-
ceutical care research, there is very little evidence to suggest 
improvement in QoL (measured by this generic instrument) 
after pharmaceutical care interventions (Billups et al 2000; 
Okano et al 2001; Schultz 2001; Vivian 2002). Several 
studies have supported the notion that existing generic QoL 
instruments may lack the speciﬁ  city and sensitivity required 
to express changes as a result of Pharmaceutical Care inter-
ventions (Billups et al 2000; Malone et al 2001; Kheir et al 
2004). The absence of a QoL instrument speciﬁ  cally designed 
for use in Pharmaceutical Care could be a possible reason 
for the difﬁ  culty in detecting improvement in QoL domains 
as a result of pharmaceutical care interventions (Kheir et al 
2004). The development of a speciﬁ  c instrument to measure 
the impact of pharmaceutical care on QoL may optimize the 
assessment of intervention outcomes, if sufﬁ  ciently sensible 
to detect truly positive outcomes (Schultz 2001; Pickard and 
Hung 2006).
The SF-36 is a self-completed instrument, but it was 
administrated by the researcher because of the low literacy 
of patients. The researcher’s lack of experience to apply 
the SF-36 might have inﬂ  uenced in results. The literature 
emphasize that pharmacists’ inability to apply the instrument 
might cause to negative results in QoL (Bentley et al 1998; 
Kheir et al 2004).
The small sample size (30 patients) allowed us to detect 
signiﬁ  cant ﬁ  nal differences in DRPs and QoL results. How-
ever, several studies demonstrated that the small samples 
used in ambulatory settings and community pharmacy studies 
were associated with poor or insigniﬁ  cant QoL outcomes 
(Carter et al 1997; Mehos et al 2000; Vivian 2002; Pickard 
and Hung 2006). Thus, for generalizability of results, larger 
size samples would naturally be needed.
Because this study was conducted in only one setting, 
our results may not be extrapolated to populations in Brazil 
or elsewhere.
Conclusion
Study participants were largely of low literacy, with high 
prevalence of chronic health conditions and high medica-
tion consumption. Inadequate drug therapy led to various 
DRPs, particularly related to the safety domain, which caused 
other health problems. Despite the limitations that may Therapeutics and Clinical Risk Management 2007:3(6) 997
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have affected the ability to generalize the results, this study 
demonstrates that the humanistic and behavioral interventions 
based on the Pharmaceutical Care model have the ability to 
reduce DRPs, and improve the QoL of elderly outpatients.
The researcher pharmacist did not discuss with the 
patients on the answers of the SF-36 in the base line. There-
fore, the ﬁ  rst results had not inﬂ  uenced the effect of the PCP 
when the questionnaire was repeated 12-months later.
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Appendix A
Classiﬁ  cation of drug-related problems, according to the 
Consensus of Granada (2002)
Drug-related   Drug-related problem type
 need 
Necessity  Type 1 – Patient does not use the drug he or she 
needs
  Type 2 – Patient uses a drug he or she does not need
Effectiveness  Type 3 – Patient does not respond to the drug
  Type 4 – Patient uses a dose, interval, or 
  duration inferior to the one needed
Safety  Type 5 – Patient uses a drug that produces an 
  adverse drug reaction
  Type 6 – Patient uses a dose, interval, or 
  duration superior to the one needed